

## Press Release: Triangle Insights Group Opens RTP Office

Research Triangle Park, NC: November 12, 2013

## Premier life sciences consulting firm serves global clients from headquarters in Research Triangle Park

Triangle Insights Group, a strategy consulting firm serving leaders across the life sciences industry, announced today that it has opened its headquarters office in Research Triangle Park. The firm, which advises clients on strategic commercialization, portfolio design, licensing diligence, and clinical development decisions, anticipates its headcount in the region expanding to twenty five consultants and analysts over the next three years.

"While our client base is global, we have found an incredible talent pool in the Triangle and look forward to nurturing our strong ties with the local business and academic communities," said Chris Apolito, one of Triangle Insights' four founding partners.

From the new office, Triangle Insights will provide services to clients who develop and commercialize therapeutics, diagnostics, and medical devices. "We are collaboration-focused. That extends to the close partnership we forge with all of our clients as well as the collaborative culture we have built within the firm," said Barrett Rankin, another founding partner. "Our new office layout fosters a high level of team interaction."

For more information about the office opening, visit <u>www.triangleinsights.com</u> or call (919) 813-6079.

## About Triangle Insights Group

Headquartered in Research Triangle Park, Triangle Insights Group, LLC is a strategy consulting firm providing guidance on the most critical business issues to leaders in life sciences organizations. The firm's approach combines deep knowledge of the industry across therapeutic areas and functional groups, with a dedication to creativity and disciplined critical thinking. Recommendations from Triangle Insights Group are original, relevant to the industry environment, and supported by rigorous analytics. Clients of Triangle Insights Group include large pharmaceutical companies, emerging biotechnology firms, diagnostics manufacturers, medical device companies, and private equity investors.